Given the variety of functions, combined with the potential number of isoforms of CD44 expressed in cancer cells, variations in the heavy chain and light chain sequences of the different anti-CD44 mAbs, as well as variations in the targeted antigen sequences, it is unlikely that the number of available mAbs is sufficient. Here, CD44 is linked to cancer.